Bertil Blok1, Philip Van Kerrebroeck2, Stefan de Wachter3, Alain Ruffion4, Frank Van der Aa5, Ranjana Jairam2, Marie Perrouin-Verbe6, Sohier Elneil7. 1. Department of Urology, Erasmus MC, Rotterdam, The Netherlands. 2. Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands. 3. Department of Urology, University Hospital Antwerpen, Edegem, Belgium. 4. Department of Urology, Hôpital Lyon Sud, Pierre Bénite, Lyon, France. 5. Department of Urology, UZ Leuven, Leuven, Belgium. 6. Department of Urology, University Hospital of Nantes, Nantes, France. 7. Department of Uro-Neurology, National Hospital of Neurology and Neurosurgery, London, United Kingdom.
Abstract
AIMS: The primary aim of the RELAX-OAB study is to confirm the safety and efficacy of the Axonics r-SNM System, a miniaturized, rechargeable SNM system. METHODS: A total of 51 OAB patients were implanted in a single-stage implant procedure. These results represent the 3-month outcomes. Subject outcomes were evaluated using 3-day bladder diaries and quality of life questionnaires. RESULTS: A total of 31 of 34 patients (91%) that responded during an initial trial period ("Test Responders") continued to benefit from therapy with the Axonics r-SNM System at 3-months, defined as symptom improvement of ≥50% reduction in urinary voids or incontinence episodes or a return to <8 voids per day. Subjects who were Test Responders showed a statistically and clinically meaningful improvement in all aspects of quality of life (ICIQ-OABqol). No serious device-related adverse events (SADEs) occurred, and there were no unanticipated adverse events (UAEs). One subject was explanted due to an infection at the implant site and 19.6% of subjects experienced device related adverse events, most notably discomfort due to stimulation, which was resolved with reprogramming. CONCLUSIONS: The Axonics r-SNM System provides safe and effective SNM therapy with objective improvement in 91% of subjects. The data also demonstrates a significant improvement in all domains of quality of life. This miniaturized, rechargeable system is designed to last 15 or more years and is expected to provide clinical and cost benefits over current non-rechargeable systems by eliminating replacement surgeries.
AIMS: The primary aim of the RELAX-OAB study is to confirm the safety and efficacy of the Axonics r-SNM System, a miniaturized, rechargeable SNM system. METHODS: A total of 51 OABpatients were implanted in a single-stage implant procedure. These results represent the 3-month outcomes. Subject outcomes were evaluated using 3-day bladder diaries and quality of life questionnaires. RESULTS: A total of 31 of 34 patients (91%) that responded during an initial trial period ("Test Responders") continued to benefit from therapy with the Axonics r-SNM System at 3-months, defined as symptom improvement of ≥50% reduction in urinary voids or incontinence episodes or a return to <8 voids per day. Subjects who were Test Responders showed a statistically and clinically meaningful improvement in all aspects of quality of life (ICIQ-OABqol). No serious device-related adverse events (SADEs) occurred, and there were no unanticipated adverse events (UAEs). One subject was explanted due to an infection at the implant site and 19.6% of subjects experienced device related adverse events, most notably discomfort due to stimulation, which was resolved with reprogramming. CONCLUSIONS: The Axonics r-SNM System provides safe and effective SNM therapy with objective improvement in 91% of subjects. The data also demonstrates a significant improvement in all domains of quality of life. This miniaturized, rechargeable system is designed to last 15 or more years and is expected to provide clinical and cost benefits over current non-rechargeable systems by eliminating replacement surgeries.
Authors: Zhonghua Ouyang; Nikolas Barrera; Zachariah J Sperry; Elizabeth C Bottorff; Katie C Bittner; Lance Zirpel; Tim M Bruns Journal: Med Biol Eng Comput Date: 2022-03-29 Impact factor: 3.079
Authors: Ruth Louise Poole; Megan Dale; Helen Morgan; Tosin Oladapo; Rebecca Brookfield; Rhys Morris Journal: Appl Health Econ Health Policy Date: 2021-12-29 Impact factor: 3.686
Authors: Bertil Blok; Philip Van Kerrebroeck; Stephan de Wachter; Alain Ruffion; Frank Van der Aa; Marie Aimée Perrouin-Verbe; Sohier Elneil Journal: Neurourol Urodyn Date: 2020-04-03 Impact factor: 2.696